<生产厂家价格>

曙红Y(醇溶)

曙红Y(醇溶)用途

曙红Y是一种染料分子。曙红Y成本低,可用性好,在有机合成中作为光氧化还原催化剂有着广泛的应用[1]。

曙红Y(醇溶)名称

[ CAS 号 ]:
15086-94-9

[ 中文名 ]:
溶剂红 43

[ 英文名 ]:
Eosin Y

[中文别名 ]:

[英文别名 ]:

Bromeosin
D & C Red no. 21
eosine acid
eosine lactonique
TetrabroMofluorescein
C.I. Solvent Red 43
MFCD00036189
D and C Red No. 21
Eosin Y alcohol
Japan Red 223

曙红Y(醇溶)生物活性

[ 描述 ]:

曙红Y是一种染料分子。曙红Y成本低,可用性好,在有机合成中作为光氧化还原催化剂有着广泛的应用[1]。

[ 相关类别 ]:

研究领域 >> 其他

信号通路 >> 其他 >> 其他

[参考文献]

[1]. Hari DP, et al. Synthetic applications of eosin Y in photoredox catalysis. Chem Commun (Camb). 2014;50(51):6688-6699.

曙红Y(醇溶)物理化学性质

[ 密度 ]:
1.02 g/mL at 20ºC

[ 沸点 ]:
640.3ºC at 760 mmHg

[ 熔点 ]:
295ºC

[ 分子式 ]:
C₂₀H₈Br₄O₅

[ 分子量 ]:
691.854

[ 精确质量 ]:
687.674377

[ PSA ]:
93.40000

[ LogP ]:
6.12210

[ 外观性状 ]:
橙色至红色粉末

[ 折射率 ]:
1.757

[ 储存条件 ]:
室温

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
H2O: 0.1 g/mL, dark red

曙红Y(醇溶)MSDS

曙红Y(醇溶)毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: LM5800000

CHEMICAL NAME :: Fluorescein, 2',4',5',7'-tetrabromo-

CAS REGISTRY NUMBER :: 15086-94-9

BEILSTEIN REFERENCE NO. :: 0063410

LAST UPDATED :: 199710

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C20-H8-Br4-O5

MOLECULAR WEIGHT :: 647.92

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 450 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Amphibian - frog

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :: DNA repair

TEST SYSTEM :: Bacteria - Bacillus subtilis

DOSE/DURATION :: 2 mg/disc

REFERENCE :: TRENAF Kenkyu Nenpo--Tokyo-toritsu Eisei Kenkyusho. Annual Report of Tokyo Metropolitan Research Laboratory of Public Health. (Tokyo-toritsu Eisei Kenkyusho, 24-1, 3-chome, Hyakunin-cho, Shin-juku-ku, Tokyo 160, Japan) V.1- 1949/50- Volume(issue)/page/year: 27,153,1976 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 15,183,1977 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 15,183,1977 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - T0363 No. of Facilities: 347 (estimated) No. of Industries: 2 No. of Occupations: 5 No. of Employees: 7340 (estimated) No. of Female Employees: 1584 (estimated)

曙红Y(醇溶)安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
R36

[ 安全声明 (欧洲) ]:
26

[ 危险品运输编码 ]:
UN 1170 3/PG 2

[ WGK德国 ]:
3

[ RTECS号 ]:
LM5850000

[ 海关编码 ]:
32041919

曙红Y(醇溶)合成路线

曙红Y(醇溶)上下游产品

曙红Y(醇溶)上游产品

曙红Y(醇溶)下游产品

曙红Y(醇溶)文献

PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.

Gastroenterology 147(6) , 1405-16.e7, (2014)

New drug targets are urgently needed for the treatment of patients with pancreatic ductal adenocarcinoma (PDA). Nearly all PDAs contain oncogenic mutations in the KRAS gene. Pharmacological inhibition...

Chondrogenesis of human bone marrow mesenchymal stromal cells in highly porous alginate-foams supplemented with chondroitin sulfate.

Mater. Sci. Eng. C. Mater. Biol. Appl. 50 , 160-72, (2015)

To overcome the limited intrinsic cartilage repair, autologous chondrocyte or bone-marrow-derived mesenchymal stromal cell (BM-MSC) was implanted into cartilage defects. For this purpose suitable bioc...

Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.

Sci. Rep. 5 , 8029, (2015)

Novel molecularly targeted agents that block the development and metastasis of human brain metastatic breast cancer hold great promise for their translational value. In this study, we constructed a no...

更多文献